Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Supriya Lifescience Ltd (SUPRIYA) is currently trading at 837.30 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Supriya Lifescience Limited is an India‑based integrated API manufacturer and exporter focused on niche therapeutic APIs including anesthetics, anti‑histamines, vitamins and anti‑asthmatics, with regulated market approvals (USFDA, EDQM, ANVISA, Health Canada and others) and a global presence across 120+ countries supplying over 1,500 customers. Q3 FY26 revenue was INR 2064 Mn (▲11% YoY) with strong profitability: EBITDA INR 720.8 Mn (34.9%) and PAT INR 496.8 Mn (24.1%), reflecting resilience driven by high‑margin niche APIs and export demand despite margin normalization from new product scaling and higher employee and other expenses. Supriya Lifescience derives roughly 74% of 9M FY26 revenue from backward‑integrated products and has purposefully invested in Module E and Ambernath formulation capacity, positioning the company to convert recent regulatory approvals and launches into larger regulated‑market volumes over FY27 and beyond. Management maintains guidance for ~20% annual revenue growth and a FY27 revenue target near INR 1,000 crore, underpinned by the Ambernath FDF commissioning, ongoing product launches (CVS, ADHD, liquid anesthetics), and a disclosed ten‑year exclusive European supply contract expected to start contributing from FY27.
Over the past 52 weeks, Supriya Lifescience Ltd has traded between a low of ₹545.65 and a high of ₹1,085.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Supriya Lifescience Ltd has a market capitalization of approximately 6,799.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Supriya Lifescience Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 32.51 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,799.19 Cr, Supriya Lifescience Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Supriya Lifescience Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Supriya Lifescience Ltd is 32.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 52-week high cited was ₹1,085.
FY26 revenue grew 19% YoY to ₹828 crore, as stated in the provided data.
Discovery themes featuring this stock
Regulatory/Compliance Filing
Supriya Lifescience published newspaper extracts of its Postal Ballot Notice in Financial Express (English) and Loksatta (Marathi) and filed the publication under Regulation 30 (LODR) with exchanges.
Regulatory/Compliance Filing
Supriya Lifescience filed newspaper clippings of the Postal Ballot Notice published in Financial Express (English) and Loksatta (Marathi) and requested exchanges to take the information on record.
AGM/EGM Notice
Supriya Lifescience Ltd issued a postal ballot notice to reappoint Mr. Balasaheb Sawant as Whole Time Director for 3 years from May 26, 2026; e-voting Jul 23–Aug 21, 2026; results to be declared Aug 22, 2026.
AGM/EGM Notice
Supriya Lifescience Ltd issued a postal ballot notice seeking member approval to reappoint Mr. Balasaheb Sawant as Whole Time Director (26‑May‑2026 to 25‑May‑2029). Remote e‑voting: 2026-07-23 to 2026-08-21; results: 2026-08-22.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
569.15 | 7,075 Cr | 31.89 | 15.15 | 0.79 | 47.50 | 52.11 | 32.88 | ||
215.00 | 6,974 Cr | 4.49 | 5.21 | 0.00 | 116.01 | 80.89 | 71.55 | ||
845.50 | 6,799 Cr | 32.51 | 5.68 | 0.12 | 17.46 | 23.00 | 15.41 | ||
417.80 | 6,794 Cr | 24.14 | 2.73 | 1.20 | 11.32 | 15.18 | 9.64 | ||
1411.50 | 6,500 Cr | 56.34 | 6.96 | 0.00 | 12.36 | 14.43 | 7.58 | ||
685.65 | 6,217 Cr | 33.34 | 2.93 | 0.51 | 8.22 | 9.59 | 5.36 | ||
975.00 | 5,527 Cr | 39.22 | 5.07 | 0.21 | 12.92 | 14.30 | 7.67 | ||
| Median: 7 Co. | — | 685.65 | 6,794 Cr | 32.51 | 5.21 | 0.21 | 12.92 | 15.18 | 9.64 |
Supriya Lifescience Limited is an India‑based integrated API manufacturer and exporter focused on niche therapeutic APIs including anesthetics, anti‑histamines, vitamins and anti‑asthmatics, with regulated market approvals (USFDA, EDQM, ANVISA, Health Canada and others) and a global presence across 120+ countries supplying over 1,500 customers.
Q3 FY26 revenue was INR 2064 Mn (▲11% YoY) with strong profitability: EBITDA INR 720.8 Mn (34.9%) and PAT INR 496.8 Mn (24.1%), reflecting resilience driven by high‑margin niche APIs and export demand despite margin normalization from new product scaling and higher employee and other expenses.
Supriya Lifescience derives roughly 74% of 9M FY26 revenue from backward‑integrated products and has purposefully invested in Module E and Ambernath formulation capacity, positioning the company to convert recent regulatory approvals and launches into larger regulated‑market volumes over FY27 and beyond.
Management maintains guidance for ~20% annual revenue growth and a FY27 revenue target near INR 1,000 crore, underpinned by the Ambernath FDF commissioning, ongoing product launches (CVS, ADHD, liquid anesthetics), and a disclosed ten‑year exclusive European supply contract expected to start contributing from FY27.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,739 Cr
Low Risk
32.2
37.2
1.2
5.7
1,085.50
545.65
Sales CAGR
Profit CAGR
ROE
ROCE
